NR1H4 and chronic kidney disease: A more recent study showed that FXR activation increased miR-135a-5p expression, which inhibited the activation of the transforming growth factor-β receptor 1 (TGFBR1)/TGF-β-activated kinase 1 (TAK1) pathway, ultimately resulting in the attenuation of vascular inflammation and calcification in CKD rats [127].